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ABSTRACT The main guidelines for cardiovascular disease prevention suggest that nutraceuticals could be an efficacious
tool to improve lipid pattern. Our aim was to carry out a clinical trial comparing the metabolic effects of a combined
nutraceutical containing both red yeast rice and polyunsaturated fatty acids (PUFAs) and a phytosterol-based approach in a
setting of clinical practice. This was a multicenter open study with parallel control. We consecutively enrolled 107 pharma-
cologically untreated subjects affected by primary polygenic hypercholesterolemia and metabolic syndrome, assigned to 8-week
treatment with a combined treatment with red yeast rice (Dif1Stat, including 5mg monacolin K) and 610mg PUFAs. A parallel
group of 30 subjects with similar characteristics was treated with phytosterols 1600mg/die. In the combined nutraceutical group,
compared with the baseline level, we observed a significant decrease in total cholesterol (TC; -42.50– 18.1mg/dL), low-density
lipoprotein cholesterol (LDL-C; -37.6– 13.6mg/dL), triglycerides (TG; -19.8– 25.1mg/dL), and non-HDL-C (-43.1– 17.7mg/
dL) (all P< .001). In the phytosterol-treated group, compared to the baseline level, we observed a significant decrease in TC
(-13.7– 4.3mg/dL), LDL-C (-17.6– 8.5mg/dL), and non-HDL-C (-14.1– 5.6mg/dL) (all P< .001). When comparing the
combined nutraceutical effect with that of phytosterols, we observed that the combined nutraceutical intake was associated with a
significantly higher decrease in TC, LDL-C, TG, and non-HDL-C (all P< .001). In the short term, a combined nutraceutical
containing red yeast rice and PUFAs is well tolerated and efficacious in reducing plasma lipid levels in subjects affected by
primary polygenic hypercholesterolemia and metabolic syndrome.
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INTRODUCTION
The main risk factors of cardiovascular disease (CVD)are well known, and reversing the exposure to these risk
factors is associated with a significant reduction of CVD risk.
This is particularly evident when hypercholesterolemia is
treated: a 1mmol/L decrease in low-density lipoprotein
(LDL)-cholesterolemia is associated with a 20% risk reduc-
tion of CVD events.1 However, not all recent literature agrees
on the cost-benefit ratio associated with statin treatment in
subjects in primary prevention for CVD.2 A certain number of
patients therefore refuse to continue the standard treatment
due to intolerance to it,3 or look for alternative treatments
because of their fear of statin-related side effects.4
A large amount of literature suggests that numerous nat-
ural products could have interesting preventive activities in
the management of human hyperlipidemia.5
Based on the positive results reported in literature, the Eu-
ropean Food Safety Authority (EFSA) recognized that there is
a cause-and-effect relationship between the consumption of
monacolin K from red yeast rice (daily dose about 10mg
monacolin K) and the maintenance of normal blood low-
density lipoprotein cholesterol (LDL-C) concentrations,6 and
between omega-3 polyunsaturated fatty acid (PUFA) intake
(eicosapentaenoic acid [EPA] and docosahexaenoic acid
[DHA] about 250mgper day) and normal cardiac function.7 In
this context, our aim was to carry out an open clinical trial
comparing the metabolic effects of a combined nutraceutical
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containing both red yeast rice and PUFAs and a phytosterol-
based approach in patients affected by primary polygenic
hypercholesterolemia and metabolic syndrome.
MATERIALS AND METHODS
This was a multicenter open study with parallel control.
For this study we consecutively enrolled 107 pharmaco-
logically untreated subjects (M: 58, F: 49) affected by
primary polygenic hypercholesterolemia and metabolic
syndrome,8 nondiabetic, in primary prevention for CVD.
All patients were already followed for dyslipidemia by
specialized lipid clinics, and as they already followed an
overall correct diet, they were therefore directly assigned to
an 8-week therapy with the combined treatment being tes-
ted, containing red yeast rice (Dif1Stat, including 5mg
monacolin K)9 and 610mg PUFAs (of which, 183mg EPA,
122 DHA), provided by Difass International Srl.
A parallel group of 30 subjects affected by primary
polygenic hypercholesterolemia and metabolic syndrome
was also enrolled and treated for 8 weeks with phytosterols
1600mg/die, administered in the form of a yogurt with ad-
ded phytosterols (Danacol, Danone Italia). The choice of
phytosterols as a treatment for the control group was based
on suggestions made by Italian and European guidelines10,11
for dyslipidemia management, and the dosage of 1600mg/
day was based on the widely available marketed yogurt with
this dosage, also considered as risk effective.12
The characteristics of the enrolled patients at the baseline
are resumed in Table 1. The two groups of patients resulted
cross-matched by baseline age, blood pressure, lipid, and
glucose metabolism parameters.
Safety monitoring included physical examination, vital
sign assessment, weight and height measurements, ques-
tioning about adverse events, and laboratory tests. Medica-
tion compliance was assessed by counting the number of
drug doses returned at clinic visits.
Adverse events, intercurrent diseases, and compliance
were also checked at the end of the study.
The whole study was carried out in the field of the routine
clinical practice of the units involved in the research, fol-
lowing the internal guidelines of the service, and in line with
the principles outlined in the Declaration of Helsinki (Re-
commendations guiding physicians in biomedical research
involving human subjects). All the involved subjects gave
written informed consent to the study.
For the statistical analysis, we excluded those patients who
were not compliant with the diet and/or the treatment, so that
the final sample included 84 subjects (M: 41, F: 43). The data
were entered in an apposite database and statistically ana-
lyzed with the help of SPSS 21.0, version for Windows. A
complete descriptive analysis of all studied parameters was
carried out (range, mean, standard deviation, mean standard
error, Kurtosis, Skewness), followed by a Kolmogorov-
Smirnov normality test. The comparative analysis was carried
out applying the ANOVA test followed by post-hoc Tukey’s
test to evaluate treatment associated changes, while the t-test
for unpaired samples was used to evaluate possible differ-
ences between genders or between patients with and without
metabolic syndrome. To be more prudent, a P value of less
than .01 was considered as significant for all tests.
RESULTS
Both treatments were well tolerated, and no patients had
side effects or withdrew from the study. No safety parameters
Table 1. Baseline Main Characteristics of the Subjects
Included in the Two Treatment Groups
Combined nutraceutical
group (N = 84)
Phytosterol
group (N = 30)
Mean SD Mean SD
Age (years) 52.9 11.8 51.7 12.1
BMI (kg/m2) 26.1 2.9 26.2 3.0
WC (cm) 90.6 8.2 91.3 8.3
TC (mg/dL) 258.5 13.9 256.9 12.1
HDL-C (mg/dL) 48.6 10.1 49.5 9.8
TG (mg/dL) 197.8 75.3 194.9 69.3
LDL-C (mg/dL) 169.8 16.5 167.6 17.4
Non-HDL-C (mg/dL) 209.8 11.7 208.1 13.2
GOT (U/L) 23.2 7.5 24.8 6.2
GPT (U/L) 24.4 7.7 25.4 7.6
CPK (U/L) 122.7 44.1 128.0 47.5
BMI, body mass index; CPK, creatinine-phosphokinase; GOT, glutamate
oxaloacetate transaminase; GPT, glutamate piruvate transaminase; HDL-C,
high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein choles-
terol; TC, total cholesterol; TG, triglycerides; WC, waist circumference.
FIG. 1. Main % changes occurred during the study in lipid profile
after treatment with the combined nutraceutical being tested and
phytosterols.
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(GOT, GPT, and CPK) changed significantly during the
study. No significant body changes were observed during the
study in either of the treatment groups.
The main changes that occurred in lipid profile during the
study following both treatments are resumed in Figure 1. In
the combined nutraceutical group, compared with the base-
line level, we observed a significant decrease in total cho-
lesterol (TC; -42.50– 18.1mg/dL, P< .001), LDL-C (-37.6–
13.6mg/dL, P< .001), triglyceride (TG; -19.8– 25.1mg/dL,
P< .001), and non-HDL-C (-43.1– 17.7mg/dL, P< .001).
In the phytosterol-treated group, compared with the base-
line level, we observed a significant decrease in TC (-13.7–
4.3mg/dL, P< .001), LDL-C (-17.6– 8.5mg/dL, P< .001),
and non-HDL-C (-14.1– 5.6mg/dL, P< .001). TGs were not
significantly modified in this group.
High-density lipoprotein cholesterol (HDL-C) level was
not significantly modified in either the combined nu-
traceutical or the phytosterol-treated groups.
In comparing the combined nutraceutical effect with that
of phytosterols, we observed that the combined nu-
traceutical intake was associated with a significantly higher
decrease in TC (P < .001), LDL-C (P < .001), TG (P < .001),
and non-HDL-C (P < .001) with respect to the control group.
In the combined nutraceutical group, 75% of subjects
reached an LDL-C target of less than 160mg/dL and 25% of
less than 130mg/dL. In the placebo group, 50% of subjects
reached an LDL-C target of less than 160mg/dL, and none
less than 130mg/dL.
Repeating the analysis by subgroups, similar trends were
observed in men and women and in subjects with or without
metabolic syndrome. We noted a greater decrease in TG
levels only in subjects with baseline TG > 150mg/dL treated
with the combined nutraceutical being tested, who reached
a 11% reduction (P < .001 vs. subjects with baseline TG
< 150mg/dL).
DISCUSSION
CVDs are still the most common cause of death and one
of the main causes of disability in industrialized countries,
and despite efforts toward primary prevention, many pa-
tients still remain at risk.13 Lifestyle interventions such as
diet and/or physical activity remain the most cost-effective
approach in delaying or preventing the onset of CVDs,14
especially in relatively healthy subjects.15 Weight loss (re-
duction of 7–10% of weight) and moderate intensity exer-
cise, such as walking 5–7 days per week, could be useful
tools to help blood pressure, LDL-C, and blood glucose
control. Giving up smoking is also recommended. However,
lifestyle programs are often difficult to follow for long pe-
riods, and some risk parameters, such as cholesterolemia,
are relatively resistant to changes in dietary habits and
physical activity.16 On the other hand, a relatively large
number of dietary supplements and nutraceuticals have been
studied for their supposed or demonstrated ability to safely
improve lipid patterns in humans.4,5
In our study, carried out on moderately hypercholester-
olemic subjects with metabolic syndrome, we observed that
the intake of a combined nutraceutical containing red yeast
rice and PUFAs was associated with a significant reduction
of TC (-16% – 2%), LDL-C (-22% – 3%), TG (-9%– 5%),
and non-HDL-C (-21% – 3%), and a significant increase in
HDL-C (+1.5% – 0.5%), without the modification of safety
parameters. The observed improvement in TC, LDL-C, and
non-HDL-C was also significant when compared with that
registered in a parallel group of patients treated with phy-
tosterols. Based on current evidence, we could estimate that
an LDL-C reduction of 20% is associated with a reduction in
CVD events of about 20% in the following 10 years.17
Naturally, this is only an indirect estimation, but it supports
a potential role for the use of efficacious nutraceuticals in
CVD risk reduction.
The improvement in LDL-cholesterolemia is quantita-
tively similar to that observed in other studies carried out on
combined nutraceuticals with lipid-lowering activity, con-
taining either statin-like substances18 or other components.19
The lack of a significant improvement in TG level is prob-
ably related to the large spontaneous variation of this pa-
rameter, the relatively normal level of TG in the patients
studied, and the small amount of EPA/DHA included in the
tested nutraceutical, aimed more at improving the dietary
intake of EPA/DHA for an adequate CVD prevention7 than
at reducing triglyceridemia.
Our study has certain limitations. The first are the rela-
tively small sample of enrolled patients and the short duration
of observation. This was, however, just a preliminary study
aiming to evaluate efficacy and tolerability. A further limi-
tation is that we did not test the lipid-lowering efficacy of the
single components of the nutraceutical to be tested. These are,
however, known from available literature.4 Furthermore, our
evaluation of efficacy is based on a limited quantity of lab-
oratory data and on no instrumental data. Another problem is
that the study we designed was not a randomized, double-
blind clinical trial, although the considered control group had
characteristics similar to the main one, and treatment with
phytosterols is currently suggested as a first step nutraceutical
treatment by a number of experts.20,21 This choice was also
related to the technical difficulty in creating an active com-
parator similar to a mix of red yeast rice and PUFAs. In fact,
our aim was not to compare the effect of the combined nu-
traceutical being tested with a placebo (the lipid-lowering
effect of both red yeast rice and PUFAs being widely known
from available literature), but with an active compound also
known for its cholesterol-lowering effect.
In conclusion, in the short term the tested combined nu-
traceutical is well tolerated and efficacious in reducing
plasma lipid levels in subjects affected by primary polygenic
hypercholesterolemia and metabolic syndrome.
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